The KAAACI Guidelines for Sublingual Immunotherapy

Area of Science:

• Allergy and Immunology
• Pharmacology

Background:

• Allergen immunotherapy is the sole disease-modifying treatment for allergic conditions such as allergic rhinitis and asthma.
• Sublingual immunotherapy (SLIT) is increasingly prescribed for allergies, gaining clinical traction as a viable alternative to subcutaneous immunotherapy.
• Decades of research support SLIT's efficacy, safety, and well-defined mechanisms of action.

Purpose of the Study:

• To provide an expert opinion on the use of sublingual immunotherapy (SLIT) in Korea.
• To consolidate current evidence on SLIT's mechanisms, patient selection, available products, and safety/efficacy profiles.
• To guide healthcare professionals in the practical application of SLIT for allergic diseases.

Main Methods:

• Extensive literature review conducted by specialists in allergy, pediatrics, and otorhinolaryngology.
• Development of a clinical guideline based on accumulated evidence and expert consensus.
• Focus on practical aspects of SLIT, including product information and patient management.

Main Results:

• SLIT is a well-established, safe, and effective treatment option for allergic rhinitis and asthma.
• Evidence supports SLIT as an alternative to subcutaneous immunotherapy.
• The guideline details specific SLIT products available in Korea and criteria for patient selection.

Conclusions:

• Sublingual immunotherapy (SLIT) is a valuable therapeutic option for managing allergic diseases.
• This guideline enhances understanding and practical application of SLIT for clinicians.
• SLIT offers a disease-modifying approach with a favorable safety and efficacy profile.